A Phase II Study of Imatinib Mesylate and Capecitabine in Metastatic Breast Cancer: Southwest Oncology Group Study 0338

PURPOSE: Imatinib mesylate is a potent inhibitor of the Bcr-Abl, c-kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases. Based on variable expression of c-kit and PDGFR in breast cancer, and on in vitro data supporting synergy between imatinib and capecitabine, the Southwest Onc...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Chew, Helen K., Barlow, William E., Albain, Kathy, Lew, Danika, Gown, Allen, Hayes, Daniel F., Gralow, Julie, Hortobagyi, Gabriel N., Livingston, Robert
Formato: Artigo
Idioma:Inglês
Publicado: 2008
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3510680/
https://ncbi.nlm.nih.gov/pubmed/19073506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CBC.2008.n.062
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares